Navigation Links
Pharmos Corporation Reports 2009 Third Quarter Results
Date:11/12/2009

t the current cash and cash equivalents, totaling $1.3 million as of September 30, 2009, will be sufficient to support the Company's currently planned continuing operations at least through December 31, 2009. The Company is working on securing cash resources to extend operations beyond December 31, 2009. Cowen and Company have been retained as advisors to help accelerate the process of a partnership arrangement for our lead compound, Dextofisopam. Additionally any proceeds for the sale of the New Jersey NOL's are expected to extend operations beyond December 31, 2009. The Company's expected cash expenditures in the last quarter of 2009 will be less than the first three quarters of 2009 as the Dextofisopam Phase 2b trial completed patient treatment in July and statistical analysis was completed in September 2009. The majority of ongoing costs will be general and administrative which will be significantly less than funding a clinical trial. The Company routinely pursues various funding options, including additional equity offerings, equity-like financing, strategic corporate alliances, business combinations and the establishment of product related research and development limited partnerships, to obtain additional financing to continue the development of its products and bring them to commercial markets. On April 21, 2009, the Company completed a private placement of common stock and warrants. At the closing, the Company issued 18,000,000 shares of common stock and warrants exercisable for an additional 18,000,000 shares of common stock for an aggregate purchase price of $1,800,000. The exercise price of the warrants, which have a five-year term, is $0.12 per share. The details of the financing, made by existing investors and current board members, are described in Note 2 to the financial statements. This financing would also support additional efforts to negotiate a strategic partnership or license arrangement with a pharmaceutical company. This is consistent wit
'/>"/>
SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmos Issues Business Update on Dextofisopam Trial and Financing
2. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
3. MedCath Corporation Reports Fourth Quarter Earnings
4. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
5. Dr. John Mills and Joseph Gentile Join Board of Directors of ChanTest Corporation
6. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
7. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
8. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
9. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
10. MedCath Corporation to Hold Conference Call on Fourth Quarter Results
11. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced an interim analysis ... studies pairing aldoxorubicin with either gemcitabine or ifosfamide. ... ifosfamide with escalating doses of aldoxorubicin. The combinations ... the lowest dose level of aldoxorubicin (170 mg/m2), ...
(Date:5/4/2015)... YORK , May 4, 2015  FireflySci Inc., the newest member of the cuvette ... after launch, they have turned the cuvette industry on its head by offering scientists amazing support ... http://photos.prnewswire.com/prnh/20150501/213243LOGO Photo - http://photos.prnewswire.com/prnh/20150501/213244 ... ... ...
(Date:5/4/2015)... 4, 2015 The Pharmacy Workforce Center recently ... that pharmacy has shifted toward a female-dominated profession. With ... managers, there is an incredible opportunity for women to ... decade. In a new blog post ... Insights , Eden Sulzer, director of the Women ...
Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 2New Cuvette Manufacturer Delivers Fast, Easy Solutions for Even the Hardest Cuvette Experiments 3Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 2Cardinal Health Expert Discusses Latest Research On Gender Gap In Pharmacy 3
(Date:5/4/2015)... The University of California, Davis and ... initiative at UC Davis School of Medicine dedicated ... to advancing Latino health. , The program, called ... to Be Physicians, (“Prep Médico” for short) is ... and internship opportunities, a residential program, intensive language ...
(Date:5/4/2015)... Georgia (PRWEB) May 04, 2015 Each year, ... country to raise funds and awareness for breast cancer. This ... Surgery will be featured as the entertainment sponsor for the ... Cure” on May 9 at the Lenox Square Mall. , ... Atlanta race, and to raise $1.2 million. Perimeter Plastic Surgery ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a groundbreaking ceremony ... on Wednesday, April 22. , Johnson & Wales becomes the ... the re-alignment of Interstate-195. JWU’s new academic building, which will ... in Providence, is scheduled to be completed in July 2016. ... university purchased in 2012. , “It has long been our ...
(Date:5/4/2015)... May 04, 2015 The Lymphoma Research ... exclusively to funding innovative lymphoma research and serving the ... outreach initiatives and patient services – is set to ... Mayfair Farms in West Orange, NJ on June 1, ... for innovative research programs through LRF. , This year, ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Baptist ... Association/American Stroke Association’s Get With The Guidelines®-Stroke Gold ... Stroke Honor Roll. The award recognizes the hospital’s ... receive the most appropriate treatment according to nationally ... evidence. , To receive the Gold Plus Quality ...
Breaking Medicine News(10 mins):Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4
... loss to Argentina in a World Cup match in 1998 ... by 27 per cent. The fact that extreme stress and ... known to almost everyone.However, research carried out at the ... Argentina during the 1998 World Cup has provided further evidence ...
... The number of people suffering from spine problems is on ... disc and spinal canal stenosis. Herniated disc is more common ... spinal canal stenosis is common among// older people. Hitherto, both ... an incision of about 12cms to be made and the ...
... of the main concerns of teenagers heading back to school ... UT Southwestern Medical Center say that stress is one of ... stress produces increased secretion of the hormone androgen //which results ... likely to suffer from acne due to the hormonal changes ...
... new study involving twenty mothers and their full-term infants, ... regular sleep cycle. ,Dr. Sari Goldstein from Tel ... the perinatal // period helps infants coordinate their circadian ... clock that helps humans and other beings adjust to ...
... shown that smoking leads to damage of the protective reflexes ... from flowing back into the hroat and smoking causes damage ... chords if fluid enters the area, a condition known as ... by imaging the relex area before and after cigarettes. The ...
... study on both mice and humans are showing why some people ... that if you eat a fatty meal or snack - a ... cholesterol you absorb is strongly influenced by your genes. Experts know ... high fat diet is bad for you. But little has been ...
Cached Medicine News:
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... capability to quickly deliver up to 250 ... for powerful single-pulse ablation. This type of ... coldest and cleanest CO2 surgical laser available ... with the independent adjustment of pulse energy ...
... technology has allowed for perfecting mini-invasive endoscopic ... various pathologies with a considerable social impact. ... reducing the post-operatory times and represents a ... in all hospital structures.,DEKAs family of Nd:YAG ...
Medicine Products: